Vivani's implant reduces GLP-1 discontinuation rates by 30% in trials

By Q4 2027, phase 2 clinical trials of Vivani's semaglutide implant will demonstrate a 30% reduction in patient discontinuation rates compared to weekly GLP-1 injections. The data will validate the implant's efficacy in maintaining weight loss and reduce concerns about long-term adherence.

product|earnings · Prediction Market

Implied probability (Yes)

50%

Closes

2027-12-31